Literature DB >> 21920697

Achieving quality indicator benchmarks and potential impact on coronary heart disease mortality.

Harindra C Wijeysundera1, Nicholas Mitsakakis, William Witteman, Mike Paulden, Gabrielle van der Velde, Jack V Tu, Douglas S Lee, Shaun G Goodman, Robert Petrella, Martin O'Flaherty, Simon Capewell, Murray Krahn.   

Abstract

BACKGROUND: Quality indicators in coronary heart disease (CHD) measure the practice gap between optimal care and current clinical practice. However, the potential impact of achieving quality indicator benchmarks remains unknown.
METHODS: Using a validated, epidemiologic model of CHD in Ontario, Canada, we estimated the potential impact on mortality of improved utilization on CHD quality indicators from 2005 levels to recommend benchmark utilization of 90%. Eight CHD disease subgroups were evaluated, including inpatients with acute myocardial infarction (AMI), acute coronary syndromes, and heart failure, in addition to ambulatory patients who were post-acute myocardial infarction survivors, or had heart failure, chronic stable angina, hypertension, or hyperlipidemia. The primary outcome was the predicted mortality reduction associated with meeting quality indicator targets for each CHD subgroup-treatment combination.
RESULTS: In 2005, there were 10,060 CHD deaths in Ontario, representing an age-adjusted CHD mortality of 191 per 100,000 people. By meeting quality indicator utilization benchmarks, mortality could be potentially reduced by approximately 20% (95% confidence interval 17.8-21.1), representing approximately 1960 avoidable deaths. The bulk of this potential benefit was in ambulatory patients with chronic stable angina (36% of reduction) and heart failure (31% of reduction). The biggest drivers were optimizing angiotensin-converting enzyme inhibitor use in chronic stable angina patients (approximately 440 avoidable deaths) and β-blocker use in heart failure (approximately 400 avoidable deaths).
CONCLUSIONS: These findings reinforce the importance of quality indicators and could aid policy makers in prioritizing strategies to meet the goals outlined in the Canadian Heart Health Strategy and Action Plan for reducing cardiovascular mortality.
Copyright © 2011 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21920697     DOI: 10.1016/j.cjca.2011.06.005

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  3 in total

1.  Comparative-effectiveness of revascularization versus routine medical therapy for stable ischemic heart disease: a population-based study.

Authors:  Harindra C Wijeysundera; Maria C Bennell; Feng Qiu; Dennis T Ko; Jack V Tu; Duminda N Wijeysundera; Peter C Austin
Journal:  J Gen Intern Med       Date:  2014-03-08       Impact factor: 5.128

Review 2.  Decline in Cardiovascular Mortality: Possible Causes and Implications.

Authors:  George A Mensah; Gina S Wei; Paul D Sorlie; Lawrence J Fine; Yves Rosenberg; Peter G Kaufmann; Michael E Mussolino; Lucy L Hsu; Ebyan Addou; Michael M Engelgau; David Gordon
Journal:  Circ Res       Date:  2017-01-20       Impact factor: 17.367

3.  Beyond case fatality rate: using potential impact fraction to estimate the effect of increasing treatment uptake on mortality.

Authors:  Nicholas Mitsakakis; Harindra C Wijeysundera; Murray Krahn
Journal:  BMC Med Res Methodol       Date:  2013-09-04       Impact factor: 4.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.